Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Baldini C; Cassier PA; Delord JP; Simonelli M; Touat M; Yao L; Duic JP; Gozman A; Marabelle A

doi:10.1007/s11060-026-05461-2

← 뒤로

Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Journal of neuro-oncology 2026 Vol.177(2)

Baldini C, Cassier PA, Delord JP, Simonelli M, Touat M, Yao L, Duic JP, Gozman A, Marabelle A

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Baldini C, Cassier PA, et al. (2026). Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.. Journal of neuro-oncology, 177(2). https://doi.org/10.1007/s11060-026-05461-2

MLA Baldini C, et al.. "Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.." Journal of neuro-oncology, vol. 177, no. 2, 2026.

PMID 41920388

DOI 10.1007/s11060-026-05461-2

같은 제1저자의 인용 많은 논문 (2)

[Systemic treatments in older patients with cancer].
La Revue du praticien 2026
The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer.
ESMO open 2026